Contact Us
Refer a Patient
Pay My Bill 
Clinical Research at Fraser Eye
Fraser Eye proudly serves patients in Detroit throughout Michigan, providing advanced ophthalmic care supported by innovation and research. Our physicians partner with leading global companies to evaluate new treatments and technologies that may improve sight and enhance quality of life for patients.
As part of our commitment to medical advancement, we offer opportunities to participate in clinical research studies across multiple subspecialties, including cataract surgery, glaucoma, and corneal disease. Learn more about our current and completed studies below.
Cataract Surgery Studies
Evaluating the Bimatoprost Implant System with the SpyGlass Intraocular Lens (IOL)
For patients undergoing cataract surgery who also have glaucoma, this study evaluates a new combined lens and medication system designed to improve both vision and intraocular pressure control in a single procedure.
Hydrus® Microstent for Eye Pressure Reduction
For patients with mild-to-moderate glaucoma undergoing cataract surgery, this study investigates the Hydrus Microstent—a small device implanted during surgery to help lower eye pressure and reduce dependence on medication.
Glaucoma Studies
Xen 63 Stent For Eye Pressure Reduction
For patients with advanced glaucoma, the Xen 63 stent features a larger drainage pathway that may help lower eye pressure and protect vision.
For patients with glaucoma or ocular hypertension, this study is evaluating the pressure-lowering effects of the FDA-approved iStent compared to iStent combined with the FDA-approved iDose TR implant.
This study evaluates a next-generation glaucoma laser, currently approved outside the United States, against standard laser treatment for lowering eye pressure in glaucoma patients.
Evaluating the Bimatoprost Implant System with the SpyGlass Intraocular Lens (IOL)
For patients undergoing cataract surgery who also have glaucoma, this study evaluates a new combined lens and medication system designed to improve both vision and intraocular pressure control in a single procedure.
Hydrus® Microstent for Eye Pressure Reduction
For patients with mild-to-moderate glaucoma undergoing cataract surgery, this study investigates the Hydrus Microstent—a small device implanted during surgery to help lower eye pressure and reduce dependence on medication.
Why Participate in a Clinical Trial?
Participating in a clinical trial allows patients to access new and emerging treatments while helping advance the future of eye care. Potential benefits include:
- Access to investigational therapies and devices not yet on the market
- Ongoing care and monitoring by an experienced research team
- Contributing to scientific discovery that benefits future patients
All studies are conducted under strict safety protocols and ethical oversight to protect participants.
History of Clinical Research Excellence
Fraser Eye has participated in numerous clinical studies across cataract, glaucoma, and corneal care, along with a broad spectrum of ophthalmic conditions and treatments—helping advance new technologies, surgical techniques, and standards of care. While these studies are no longer enrolling, they reflect our ongoing commitment to innovation and better patient outcomes. To explore our past clinical trials, use the button below to view the full historical list.
Contact Fraser Eye
To learn more about ongoing or upcoming clinical trials at Fraser Eye—or to find out if you may qualify—please contact our Study Coordinator Hailey Moody at 586-296-7250, Ext 114.
You can also complete the form below to be added to our research interest list, and a member of our team will reach out with more information.
Closed Clinical Studies
Evaluating iVeena Eye Drop
For individuals with keratoconus, this study evaluates an investigational eye drop that may help strengthen the cornea and slow the progression of disease.
Developing a device to diagnose keratoconus
This single-visit study evaluates an advanced imaging device designed to improve the diagnosis and grading of keratoconus. This device addresses a key barrier to diagnosing keratoconus by enabling earlier and more accurate detection.
Evaluating AGN-193408 SR, a Sustained-Release Implant
This study focuses on individuals with glaucoma or ocular hypertension who have previously undergone cataract surgery. The implant gradually releases medication to reduce eye pressure over time and may lessen the need for daily drops.
Phase 3 Study of VRDN-003 for TED
For patients with Thyroid eye disease, this study evaluates an injectable treatment designed to reduce symptoms associated with Thyroid Eye Disease via an autoinjector or syringe.
Phase 3 Study of VRDN-003 for Active TED
This study evaluated an injectable treatment designed to reduce inflammation and discomfort in patients with active Thyroid Eye Disease.
Testing iDose® TR in Combination with iStent infinite®
Compared the effectiveness of combining two glaucoma devices (iDose TR and iStent infinite) versus iStent alone for controlling intraocular pressure.
Study of VRDN-001, a Monoclonal Antibody Treatment
Investigated the safety and tolerability of an IV infusion therapy administered every three weeks for Thyroid Eye Disease.
Phase 3 Study of VRDN-003 for Chronic TED (2024)
This study evaluated an injectable treatment designed to reduce inflammation and discomfort in patients with chronic Thyroid Eye Disease.
Evaluating Phentolamine Ophthalmic Solution (POS) 0.75%
Tested an eye drop designed to improve near vision for individuals with presbyopia while maintaining clear distance vision.
Study of the Bimatoprost Implant System with SpyGlass IOL
Compared two implant doses against Timolol eye drops in patients undergoing cataract surgery.
Study of PER-001 Intravitreal Implant
Assessed the safety and tolerability of a novel implant for patients with open-angle glaucoma.
Study of Bimatoprost SR (Sustained-Release)
Evaluated the long-term safety and pressure-lowering duration of a sustained-release implant for patients not well controlled with standard drops.
PER-001 Intravitreal Implant for Diabetic Eye Disease
Tested the safety of a single implant administration for managing diabetic retinopathy.
Tivansiran for Dry Eye
Conducted a safety study of Tivanisiran as a treatment for dry eye syndrome.
Bimatoprost vs. Lumigan in Glaucoma
Evaluated the efficacy and safety of unpreserved Bimatoprost compared to Lumigan in patients with ocular hypertension or glaucoma.
Ripasudil Eye Drops after Cataract Surgery
Investigated the safety and efficacy of Ripasudil eye drops in patients post-cataract surgery
Hydrus Microstent for Glaucoma
A study on the Hydrus Microstent for reducing intraocular pressure in mild to moderate open-angle glaucoma
App13007 Post Cataract Inflammation and Pain
A study assessing APP13007’s effectiveness in treating inflammation and pain following cataract surgery.
Ab-Externo XEN 45 Placement
Evaluating a new delivery of XEN in patients with glaucoma post marketing study
Bimatoprost Sustained-Release vs. SLT
A phase 3 study comparing Bimatoprost SR injections with laser treatment for glaucoma
Silicone Hydrogel Lens
A study evaluating the safety and effectiveness of a frequent replacement Silicone Hydrogel Lens
Visual Behavior Monitor (VBM) Feasibility
A study evaluating a device to help patients and surgeons in IOL selection before surgery.
Bimatoprost Sustained Release for Glaucoma
Evaluated the duration of effect of Bimatoprost Sustained Release for Patients with Open-Angle Glaucoma
Bimatoprost Sustained Release for Glaucoma
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR
Cypass System for Glaucoma
Post Approval Study of the CyPass System in Patients with Primary Open Angle Glaucoma Undergoing Cataract Surgery
Pregabalin for Visual Field Change
Prospective Study of Visual FIeld Change in Subjects with Partial Seizures Receiving Pregabalin or Placebo
Punctum Plugs for Glaucoma or Ocular Hypertension
Evaluated the Safety and Efficacy of the use of Punctum Plugs in the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Bimatoprost Sustained Release vs SLT
Evaluated the efficacy of Bimatoprost Sustained Release Injection vs Selective Laser Trabeculoplasty (SLT)